Funder: The Myositis Association
Due Dates (Anticipated): May 2027 (Letter of intent) | July 2027 (Full application)
Funding Amounts: Up to $105,000 per award over 12–24 months
Summary: Supports hypothesis-driven basic science and mechanistic research into the causes and progression of inclusion body myositis.
Key Information: Principal investigators must hold a terminal degree and be based at an accredited medical school, university, or research institute.
Description
The Cure IBM Research Fund at TMA supports basic science and mechanistic research into the biological basis of inclusion body myositis (IBM). Run by The Myositis Association in collaboration with patient advocacy organization Cure IBM, this patient-guided, multi-year initiative aims to accelerate understanding of IBM causes, pathophysiology, and disease progression.
The fund seeks clearly defined, scientifically rigorous projects that address a specific causal question or generate preliminary data for larger future studies. Proposals must examine early molecular and cellular changes in muscle fibers and their relationship to inflammatory and degenerative processes. Researchers working in other diseases with potential connections to IBM—including amyotrophic lateral sclerosis (ALS) and multisystem proteinopathy 1 (MSP1)—are encouraged to apply.
